VistaGen Therapeutics Inc
Performance History
| Key Stats | |
|---|---|
| Open | $4.31 |
| Prev. Close | $4.29 |
| EPS | -4.65 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | - |
| Market Cap | $119.71M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 4.21 | 4.61 |
| 52 Week Range | 1.62 | 24.71 |
| Ratios | |
|---|---|
| P/B Ratio | 3.25 |
| Revenue | $278.23M |
| Operating M. % | -2,441.56% |
| Earnings | -$35.47M |
| Earnings Growth % | -131.11% |
| EBITDA Margin % | -12.82% |
| ROE % | -108.75% |
| EPS | -4.65 |
Score Breakdown
All Score (70 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| VTGN | MARKET | |
|---|---|---|
| Value | 72 | 40 |
| Quality | 53 | 45 |
| Ownership | 15 | 39 |
| Growth | 72 | 45 |
| Dividends | - | 31 |
All Score (70 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About VistaGen Therapeutics Inc (VTGN)
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Shawn K. Singh J.D.
- Headquarters
- South San Francisco
- Employees
- 32
Keep an eye on VistaGen Therapeutics Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.